WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2021 |
| Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/49866 |
Resumo: | Instituto D´Or de Pesquisa e Educação. Rio de Janeiro, RJ, Brasil. |
| id |
CRUZ_4a6548a065e8d6de5885f227f8cdf04a |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/49866 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Aragão, Luiz Guilherme H. S.Oliveira, Júlia T.Temerozo, Jairo R.Mendes, Mayara A.Salerno, José AlexandrePedrosa, Carolina S. G.Puig-Pijuan, TeresaVeríssimo, Carla P.Ornelas, Isis M.Torquato, ThayanaVitória, GabrielaSacramento, Carolina Q.Rodrigues, Natalia FintelmanDias, Suelen da Silva GomesSoares, Vinicius CardosoSouza, Letícia R. Q.Karmirian, KarinaSilva, Livia GotoBiagi, DiogoCruvinel, Estela M.Dariolli, RafaelFurtado, Daniel R.Bozza, PatríciaBorges, Helena L.Souza, Thiago M. L.Guimarães, Marília Zaluar P.Rehen, Stevens K.2021-11-18T14:01:41Z2021-11-18T14:01:41Z2021ARAGÃO, Luiz Guilherme H. S. et al. WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-COV-2. PeeRJ, p. 1-21, Oct. 2021.2691-6657https://www.arca.fiocruz.br/handle/icict/4986610.7717/peerj.12262engElsevierBiologia CelularBiologia molecularVirologiaCardiologiaFarmacologiaCanabinóidesSARS-Cov-2COVID-19Cardiomiócitos derivados de iPSC humanosWIN 55,212-2Cell BiologyMolecular BiologyVirologyCardiologyPharmacologyCannabinoidsSARS-Cov-2COVID-19Human iPSC-derived cardiomyocytesWIN 55,212-2WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleInstituto D´Or de Pesquisa e Educação. Rio de Janeiro, RJ, Brasil.Instituto D´Or de Pesquisa e Educação. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa sobre o Timo. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Instituto Nacional de Ciência e Tecnologia para Inovação em Doenças de Populações Negligenciadas. Rio de Janeiro, RJ, Brasil.Instituto D´Or de Pesquisa e Educação. Rio de Janeiro, RJ, Brasil.Universidade Federal do Rio de Janeiro. Instituto de Ciências Biomédicas. Rio de Janeiro, RJ, Brasil.Instituto D´Or de Pesquisa e Educação. Rio de Janeiro, RJ, Brasil.Instituto D´Or de Pesquisa e Educação. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Instituto de Biofísica Carlos Chagas Filho. Rio de Janeiro, RJ, Brasil.Universidade Federal do Rio de Janeiro. Instituto de Ciências Biomédicas. Rio de Janeiro, RJ, Brasil.Instituto D´Or de Pesquisa e Educação. Rio de Janeiro, RJ, Brasil.Instituto D´Or de Pesquisa e Educação. Rio de Janeiro, RJ, Brasil.Instituto D´Or de Pesquisa e Educação. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Instituto Nacional de Ciência e Tecnologia para Inovação em Doenças de Populações Negligenciadas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz.. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Instituto Nacional de Ciência e Tecnologia para Inovação em Doenças de Populações Negligenciadas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz.. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz.. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz.. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Programa de Imunologia e Inflamação. Rio de Janeiro, RJ, Brasil.Instituto D´Or de Pesquisa e Educação. Rio de Janeiro, RJ, Brasil.Instituto D´Or de Pesquisa e Educação. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Instituto de Ciências Biomédicas. Rio de Janeiro, RJ, Brasil.Instituto D´Or de Pesquisa e Educação. Rio de Janeiro, RJ, Brasil.Pluricell Biotech. São Paulo, SP, Brasil.Pluricell Biotech. São Paulo, SP, Brasil.Pluricell Biotech. São Paulo, SP, Brasil / Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.Instituto D´Or de Pesquisa e Educação. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz.. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.Universidade Federal do Rio de Janeiro. Instituto de Ciências Biomédicas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Instituto Nacional de Ciência e Tecnologia para Inovação em Doenças de Populações Negligenciadas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz.. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil..Instituto D´Or de Pesquisa e Educação. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Instituto de Ciências Biomédicas. Rio de Janeiro, RJ, Brasil.Instituto D´Or de Pesquisa e Educação. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Instituto de Biologia. Departamento de Genética. Rio de Janeiro, RJ, Brasil.Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which can infect several organs, especially impacting respiratory capacity. Among the extrapulmonary manifestations of COVID-19 is myocardial injury, which is associated with a high risk of mortality. Myocardial injury, caused directly or indirectly by SARS-CoV-2 infection, can be triggered by inflammatory processes that lead to damage to the heart tissue. Since one of the hallmarks of severe COVID-19 is the “cytokine storm”, strategies to control inflammation caused by SARS-CoV-2 infection have been considered. Cannabinoids are known to have anti-inflammatory properties by negatively modulating the release of pro-inflammatory cytokines. Herein, we investigated the effects of the cannabinoid agonist WIN 55,212-2 (WIN) in human iPSC-derived cardiomyocytes (hiPSC-CMs) infected with SARS-CoV-2. WIN did not modify angiotensin-converting enzyme II protein levels, nor reduced viral infection and replication in hiPSC-CMs. On the other hand, WIN reduced the levels of interleukins six, eight, 18 and tumor necrosis factor-alpha (TNF-a) released by infected cells, and attenuated cytotoxic damage measured by the release of lactate dehydrogenase (LDH). Our findings suggest that cannabinoids should be further explored as a complementary therapeutic tool for reducing inflammation in COVID-19 patients.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/49866/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALViniciusSoares_CarolinaSacramento_etal_IOC_2021.pdfViniciusSoares_CarolinaSacramento_etal_IOC_2021.pdfapplication/pdf8735271https://www.arca.fiocruz.br/bitstream/icict/49866/2/ViniciusSoares_CarolinaSacramento_etal_IOC_2021.pdf70fd7940fc5012f7c63e68558186970fMD52icict/498662021-11-18 11:01:41.719oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352021-11-18T14:01:41Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2 |
| title |
WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2 |
| spellingShingle |
WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2 Aragão, Luiz Guilherme H. S. Biologia Celular Biologia molecular Virologia Cardiologia Farmacologia Canabinóides SARS-Cov-2 COVID-19 Cardiomiócitos derivados de iPSC humanos WIN 55,212-2 Cell Biology Molecular Biology Virology Cardiology Pharmacology Cannabinoids SARS-Cov-2 COVID-19 Human iPSC-derived cardiomyocytes WIN 55,212-2 |
| title_short |
WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2 |
| title_full |
WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2 |
| title_fullStr |
WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2 |
| title_full_unstemmed |
WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2 |
| title_sort |
WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2 |
| author |
Aragão, Luiz Guilherme H. S. |
| author_facet |
Aragão, Luiz Guilherme H. S. Oliveira, Júlia T. Temerozo, Jairo R. Mendes, Mayara A. Salerno, José Alexandre Pedrosa, Carolina S. G. Puig-Pijuan, Teresa Veríssimo, Carla P. Ornelas, Isis M. Torquato, Thayana Vitória, Gabriela Sacramento, Carolina Q. Rodrigues, Natalia Fintelman Dias, Suelen da Silva Gomes Soares, Vinicius Cardoso Souza, Letícia R. Q. Karmirian, Karina Silva, Livia Goto Biagi, Diogo Cruvinel, Estela M. Dariolli, Rafael Furtado, Daniel R. Bozza, Patrícia Borges, Helena L. Souza, Thiago M. L. Guimarães, Marília Zaluar P. Rehen, Stevens K. |
| author_role |
author |
| author2 |
Oliveira, Júlia T. Temerozo, Jairo R. Mendes, Mayara A. Salerno, José Alexandre Pedrosa, Carolina S. G. Puig-Pijuan, Teresa Veríssimo, Carla P. Ornelas, Isis M. Torquato, Thayana Vitória, Gabriela Sacramento, Carolina Q. Rodrigues, Natalia Fintelman Dias, Suelen da Silva Gomes Soares, Vinicius Cardoso Souza, Letícia R. Q. Karmirian, Karina Silva, Livia Goto Biagi, Diogo Cruvinel, Estela M. Dariolli, Rafael Furtado, Daniel R. Bozza, Patrícia Borges, Helena L. Souza, Thiago M. L. Guimarães, Marília Zaluar P. Rehen, Stevens K. |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Aragão, Luiz Guilherme H. S. Oliveira, Júlia T. Temerozo, Jairo R. Mendes, Mayara A. Salerno, José Alexandre Pedrosa, Carolina S. G. Puig-Pijuan, Teresa Veríssimo, Carla P. Ornelas, Isis M. Torquato, Thayana Vitória, Gabriela Sacramento, Carolina Q. Rodrigues, Natalia Fintelman Dias, Suelen da Silva Gomes Soares, Vinicius Cardoso Souza, Letícia R. Q. Karmirian, Karina Silva, Livia Goto Biagi, Diogo Cruvinel, Estela M. Dariolli, Rafael Furtado, Daniel R. Bozza, Patrícia Borges, Helena L. Souza, Thiago M. L. Guimarães, Marília Zaluar P. Rehen, Stevens K. |
| dc.subject.other.pt_BR.fl_str_mv |
Biologia Celular Biologia molecular Virologia Cardiologia Farmacologia Canabinóides SARS-Cov-2 COVID-19 Cardiomiócitos derivados de iPSC humanos WIN 55,212-2 |
| topic |
Biologia Celular Biologia molecular Virologia Cardiologia Farmacologia Canabinóides SARS-Cov-2 COVID-19 Cardiomiócitos derivados de iPSC humanos WIN 55,212-2 Cell Biology Molecular Biology Virology Cardiology Pharmacology Cannabinoids SARS-Cov-2 COVID-19 Human iPSC-derived cardiomyocytes WIN 55,212-2 |
| dc.subject.en.pt_BR.fl_str_mv |
Cell Biology Molecular Biology Virology Cardiology Pharmacology Cannabinoids SARS-Cov-2 COVID-19 Human iPSC-derived cardiomyocytes WIN 55,212-2 |
| description |
Instituto D´Or de Pesquisa e Educação. Rio de Janeiro, RJ, Brasil. |
| publishDate |
2021 |
| dc.date.accessioned.fl_str_mv |
2021-11-18T14:01:41Z |
| dc.date.available.fl_str_mv |
2021-11-18T14:01:41Z |
| dc.date.issued.fl_str_mv |
2021 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
ARAGÃO, Luiz Guilherme H. S. et al. WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-COV-2. PeeRJ, p. 1-21, Oct. 2021. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/49866 |
| dc.identifier.issn.pt_BR.fl_str_mv |
2691-6657 |
| dc.identifier.doi.none.fl_str_mv |
10.7717/peerj.12262 |
| identifier_str_mv |
ARAGÃO, Luiz Guilherme H. S. et al. WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-COV-2. PeeRJ, p. 1-21, Oct. 2021. 2691-6657 10.7717/peerj.12262 |
| url |
https://www.arca.fiocruz.br/handle/icict/49866 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Elsevier |
| publisher.none.fl_str_mv |
Elsevier |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/49866/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/49866/2/ViniciusSoares_CarolinaSacramento_etal_IOC_2021.pdf |
| bitstream.checksum.fl_str_mv |
5a560609d32a3863062d77ff32785d58 70fd7940fc5012f7c63e68558186970f |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1798324675881730048 |